Verona Pharma (VRNA) Stock Forecast & Price Target

Compare

― Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRNA Analyst Ratings

Currently, no data available

Based on NaN analysts giving stock ratings to

Verona

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRNA Stock 12 Month Forecast

There Are No Analyst Ratings for VRNA In The Last 3 Months.

Highest Price Target―

Average Price Target―

Lowest Price Target―

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

VRNA Financial Forecast

VRNA Earnings Forecast

Next quarter’s earnings estimate for VRNA is $0.14 with a range of -$0.10 to $0.55. The previous quarter’s EPS was >-$0.01. VRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year VRNA has Performed in-line its overall industry.

VRNA Sales Forecast

Next quarter’s sales forecast for VRNA is $115.53M with a range of $97.68M to $159.00M. The previous quarter’s sales results were $104.36M. VRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year VRNA has Performed in-line its overall industry.

Detailed List of Analyst Forecasts

Olivia Brayer

Cantor Fitzgerald

$100

Buy

―

Reiterated

10/07/25

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

Ram Selvaraju

H.C. Wainwright

$90→$107

Hold

―

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan Pachaiyappan

Roth MKM

$116→$107

Hold

―

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas Shrader

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon Lee

Truist Financial

$100→$107

Hold

―

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen Rahimi

Piper Sandler

$160→$107

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Tiago Fauth

Wells Fargo

$138→$107

Hold

―

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward Nash

Canaccord Genuity

$106→$107

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew Tsai

Jefferies

$140→$107

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara Bancroft

TD Cowen

$100→$107

Hold

―

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Olivia Brayer

Cantor Fitzgerald

$100

Buy

―

Reiterated

10/07/25

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

Ram Selvaraju

H.C. Wainwright

$90→$107

Hold

―

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan Pachaiyappan

Roth MKM

$116→$107

Hold

―

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas Shrader

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon Lee

Truist Financial

$100→$107

Hold

―

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen Rahimi

Piper Sandler

$160→$107

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Tiago Fauth

Wells Fargo

$138→$107

Hold

―

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward Nash

Canaccord Genuity

$106→$107

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew Tsai

Jefferies

$140→$107

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara Bancroft

TD Cowen

$100→$107

Hold

―

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verona Pharma

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+13.23%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +13.23% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+30.90%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +30.90% per trade.

1 Year

Olivia BrayerCantor Fitzgerald

Success Rate

2/3 ratings generated profit

Average Return

+32.20%

reiterated a buy rating 2 months ago

Copying Olivia Brayer's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +32.20% per trade.

2 Years

xxx

Success Rate

2/3 ratings generated profit

Average Return

+32.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +32.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRNA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRNA has received 12 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. VRNA average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

VRNA Stock Forecast FAQ

What is VRNA’s average 12-month price target, according to analysts?

Currently, no data Available

What is VRNA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for VRNA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRNA a Buy, Sell or Hold?

Currently, no data Available

What is Verona Pharma’s price target?

Currently, no data Available

What do analysts say about Verona Pharma?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of VRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Verona Pharma (VRNA) Stock Forecast & Price Target

VRNA Analyst Ratings

VRNA Stock 12 Month Forecast

VRNA Financial Forecast

VRNA Earnings Forecast

VRNA Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Verona Pharma

VRNA Analyst Recommendation Trends

VRNA Stock Forecast FAQ

Detailed List of Analyst Forecasts